McBane, Robert D.
Torres Roldan, Victor D.
Niven, Alexander S.
Pruthi, Rajiv K.
Moreno Franco, Pablo
Linderbaum, Jane A.
Casanegra, Ana I.
Oyen, Lance J.
Houghton, Damon E.
Marshall, Ariela L.
Ou, Narith N.
Siege, Jason L.
Wysokinski, Waldemar E.
Padrnos, Leslie J.
Rivera, Candido E.
Flo, Gayle L.
Shamoun, Fadi E.
Silvers, Scott M.
Nayfeh, Tarek
Urtecho Suarez, Meritxell
Shah, Sahrish
Benkhadra, Raed
Mohir Saadi, Samer
Firwana, Mohamed
Jawaid, Tabinda
Amin, Mustapha
Prokop, Larry J.
Hassan Murad, M.
2020-09-07T18:05:30Z
2020-09-07T18:05:30Z
2020
0025-6196
https://doi.org/10.1016/j.mayocp.2020.08.030
http://hdl.handle.net/20.500.12010/12850
A higher risk of thrombosis has been described as a prominent feature of COVID-19. This
systematic review synthesizes current data on thrombosis risk, prognostic implications, and
anticoagulation effects in COVID-19. We included 37 studies from 4,070 unique citations.
Meta-analysis was performed when feasible. Coagulopathy and thrombotic events were
frequent among patients with COVID-19, and further increased in those with more severe
forms of the disease. We also present guidance on the prevention and management of
thrombosis from a multidisciplinary panel of specialists from the Mayo Clinic. The current
certainty of evidence is generally very low, and continues to evolve.
64 páginas
image/jepg
eng
Mayo Clinic Proceedings
reponame:Expeditio Repositorio Institucional UJTL
instname:Universidad de Bogotá Jorge Tadeo Lozano
Anticoagulation
COVID-19
Anticoagulation in COVID-19: A systematic review, meta-analysis and rapid guidance from the mayo clinic
Artículo
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
info:eu-repo/semantics/embargoedAccess
info:eu-repo/semantics/acceptedVersion
Acceso restringido
https://doi.org/10.1016/j.mayocp.2020.08.030
http://purl.org/coar/resource_type/c_2df8fbb1